Axcella Health Inc AXLA:NASDAQ

Last Price$2.74Cboe Previous Close - Real-Time Last Sale as of 3:59PM ET 8/16/22
Cboe Real-Time Quotes
Today's Change+0.01(0.37%)
Bid (Size)$2.56 (300)
Ask (Size)$2.73 (100)
Day Low / High$2.66 - 2.74
Volume31.2 K
  • Latest Stories
  • Commentary and Analysis
-- Earnings Flash (AXLA) AXCELLA THERAPEUTICS Reports Q2 Loss $-0.40
7:38AM ET 8/12/2022 MT Newswires

...

--HC Wainwright Cuts Axcella Health's Price Target to $8 From $14, Keeps Buy Rating
10:26AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Lifts Axcella Health's Price Target to $9 From $7 on AXA1125/Long COVID Data; Outperform Rating Kept
6:39AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--SVB Securities Adjusts Axcella Health's Price Target to $6 From $9, Keeps Outperform Rating
6:03AM ET 8/03/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Wedbush Cuts Axcella Health's Price Target to $7 From $10 on Termination of AXA1665/OHE Trial; Outperform Rating Kept
6:55AM ET 5/27/2022 MT Newswires

Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $7 to $19, according to analysts polled by Capital IQ. (MT...

Axcella Completes Patient Enrollment for Phase 2a Long COVID-19 Trial
8:33AM ET 5/26/2022 MT Newswires

Axcella (AXLA) said Thursday it has completed the enrollment of 40 patients into a phase 2a trial of AXA1125 as a potential treatment for long COVID-19, a...

--Chardan Lowers Axcella Health's Price Target to $7 From $12, Buy Rating Kept
11:54AM ET 5/09/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

-- Earnings Flash (AXLA) AXCELLA THERAPEUTICS Reports Q1 Loss $-0.46
7:01AM ET 5/05/2022 MT Newswires

...

SVB Leerink Trims Axcella Health's Price Target to $9 From $10, Maintains Outperform Rating
10:49AM ET 3/31/2022 MT Newswires

Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $9 to $19, according to analysts polled by Capital IQ. (MT...

Wedbush Trims Axcella Health's Price Target to $10 From $11, Keeps Outperform Rating
8:39AM ET 3/31/2022 MT Newswires

Axcella Health (AXLA) has an average rating of outperform and price targets ranging from $9 to $19, according to analysts polled by Capital IQ. (MT...